Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas

被引:109
作者
Feldman, A. L. [1 ]
Sun, D. X. [1 ]
Law, M. E. [1 ]
Novak, A. J. [2 ]
Attygalle, A. D. [3 ]
Thorland, E. C. [1 ]
Fink, S. R. [1 ]
Vrana, J. A. [1 ]
Caron, B. L. [1 ]
Morice, W. G. [1 ]
Remstein, E. D. [1 ]
Grogg, K. L. [1 ]
Kurtin, P. J. [1 ]
Macon, W. R. [1 ]
Dogan, A. [1 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Hematol, Rochester, MN 55905 USA
[3] Royal Marsden Hosp, Dept Histopathol, London SW3 6JJ, England
关键词
peripheral T-cell lymphoma; Syk; tyrosine kinase; phosphorylation;
D O I
10.1038/leu.2008.77
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Peripheral T-cell lymphomas (PTCLs) are fatal in the majority of patients and novel treatments, such as protein tyrosine kinase (PTK) inhibition, are needed. The recent finding of SYK/ITK translocations in rare PTCLs led us to examine the expression of Syk PTK in 141 PTCLs. Syk was positive by immunohistochemistry (IHC) in 133 PTCLs (94%), whereas normal T cells were negative. Western blot on frozen tissue (n = 6) and flow cytometry on cell suspensions (n = 4) correlated with IHC results in paraffin. Additionally, western blot demonstrated that Syk-positive PTCLs show tyrosine (525/526) phosphorylation, known to be required for Syk activation. Fluorescence in situ hybridization showed no SYK/ITK translocation in 86 cases. Overexpression of Syk, phosphorylation of its Y525/526 residues and the availability of orally available Syk inhibitors suggest that Syk merits further evaluation as a candidate target for pharmacologic PTK inhibition in patients with PTCL.
引用
收藏
页码:1139 / 1143
页数:5
相关论文
共 25 条
[1]   Functional role for Syk tyrosine kinase in natural killer cell-mediated natural cytotoxicity [J].
Brumbaugh, KM ;
Binstadt, BA ;
Billadeau, DD ;
Schoon, RA ;
Dick, CJ ;
Ten, RM ;
Leibson, PJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (12) :1965-1974
[2]   Differential regulation by leukotrienes and calcium of Fcγ receptor-induced phagocytosis and Syk activation in dendritic cells versus macrophages [J].
Canetti, Claudio ;
Aronoff, David M. ;
Choe, Mun ;
Flamand, Nicolas ;
Wettlaufer, Scott ;
Toews, Galen B. ;
Chen, Gwo-Hsiao ;
Peters-Golden, Marc .
JOURNAL OF LEUKOCYTE BIOLOGY, 2006, 79 (06) :1234-1241
[3]  
CHAN AC, 1994, J IMMUNOL, V152, P4758
[4]   SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma [J].
Chen, Linfeng ;
Monti, Stefano ;
Juszczynski, Przemyslaw ;
Daley, John ;
Chen, Wen ;
Witzig, Thomas E. ;
Habermann, Thomas M. ;
Kutok, Jeffery L. ;
Shipp, Margaret A. .
BLOOD, 2008, 111 (04) :2230-2237
[5]   Peripheral T-cell lymphoma with follicular involvement and a CD4+/bcl-6+phenotype [J].
de Leval, L ;
Savilo, E ;
Longtine, J ;
Ferry, JA ;
Harris, NL .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (03) :395-400
[6]   Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma -: The MD Anderson Cancer Center experience [J].
Escalón, MP ;
Liu, NS ;
Yang, Y ;
Hess, M ;
Smith, TL ;
Dang, NH .
CANCER, 2005, 103 (10) :2091-2098
[7]   Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth [J].
Gururajan, Murali ;
Dasu, Trivikram ;
Shahidain, Seif ;
Jennings, C. Darrell ;
Robertson, Darrell A. ;
Rangnekar, Vivek M. ;
Bondada, Subbarao .
JOURNAL OF IMMUNOLOGY, 2007, 178 (01) :111-121
[8]   Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma. B cells from tumor-infiltrating nonmalignant B cells [J].
Irish, Jonathan M. ;
Czerwinski, Debra K. ;
Nolan, Garry P. ;
Levy, Ronald .
BLOOD, 2006, 108 (09) :3135-3142
[9]  
Jaffe ES, 2001, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, P189
[10]   Syk-dependent mTOR activation in follicular lymphoma cells [J].
Leseux, Ludivine ;
Hamdi, Safouane M. ;
al Saati, Talal ;
Capilla, Florence ;
Recher, Christian ;
Laurent, Guy ;
Bezombes, Christine .
BLOOD, 2006, 108 (13) :4156-4162